NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

GMED | NYSE

$78.68 -$0.28 | -0.35%
TREND SIGNAL:Signal available — unlock to view |2026-10-21

Company Overview:

Market Cap: $10.65B
Trailing PE: 20.1x
FWD PE *: 15.4x
Payout Ratio (TTM): —
52-Week Range: $59.51 - $101.40

* Forward PE is based on street estimates.

10 Year GMED Performance Metrics:

Total Return (with DRIP): 238.4% (12.97% CAGR)
Total Return (no DRIP): 238.4% (12.97% CAGR)
Share Price: 240.8% (13.04% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $33,841
Total Return $ (with DRIP): $23,841
GMED Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
GMED Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
Combined 55% Lifetime Discount

GMED Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

GMED - Revenue
GMED Revenue CAGR:1Y: 5.94%2Y: 11.98%5Y: 25.76%10Y: 19.10%
GMED - Earnings Per Share (EPS)
GMED EPS CAGR:1Y: -26.17%2Y: 118.69%5Y: 22.42%10Y: 15.08%
GMED - Net Income
GMED Net Income CAGR:1Y: -25.28%2Y: 118.46%5Y: 29.54%10Y: 19.37%
GMED - EBITDA
GMED EBITDA CAGR:1Y: 44.16%2Y: 48.55%5Y: 28.73%10Y: 20.08%
GMED - Free Cash Flow
GMED Free Cash Flow CAGR:1Y: 571.30%2Y: 158.33%5Y: 28.29%10Y: 30.59%
GMED - Free Cash Flow / Share
GMED Free Cash Flow / Share CAGR:1Y: 570.52%2Y: 158.16%5Y: 20.86%10Y: 26.13%
GMED - Operating Income
GMED Operating Income CAGR:1Y: 156.83%2Y: 98.47%5Y: 33.63%10Y: 17.82%
GMED - Gross Profit
GMED Gross Profit CAGR:1Y: 10.39%2Y: 21.78%5Y: 23.98%10Y: 18.00%
GMED - Shares Outstanding
GMED Shares Outstanding CAGR:1Y: 0.65%2Y: 0.15%5Y: 5.83%10Y: 3.60%
GMED - Share Buybacks
GMED Share Buybacks CAGR:1Y: 444.23%2Y: 861.74%5Y: 0.00%10Y: 0.00%
GMED - Stock-Based Comp
GMED Stock-Based Comp CAGR:1Y: -1.72%2Y: 2.20%5Y: 11.89%10Y: 16.44%
GMED - Expenses
GMED Expenses CAGR:1Y: -35.67%2Y: 9.23%5Y: 31.65%10Y: 11.90%
GMED - Revenue by Segment
GMED Revenue CAGR:1Y: 5.94%2Y: 11.98%5Y: 25.76%10Y: 19.10%
GMED - Revenue by Region
GMED Revenue CAGR:1Y: 5.94%2Y: 11.98%5Y: 25.76%10Y: 19.10%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

GMED - REVENUE: Actual + Estimates
GMED Actual Revenue CAGR:1Y: 5.94%2Y: 11.98%5Y: 25.76%10Y: 19.10%
GMED - EPS: Actual + Estimates
GMED Actual EPS CAGR:1Y: -26.17%2Y: 118.69%5Y: 22.42%10Y: 15.08%
GMED - NET INCOME: Actual + Estimates
GMED Actual Net Income CAGR:1Y: -25.28%2Y: 118.46%5Y: 29.54%10Y: 19.37%
GMED - EBITDA: Actual + Estimates
GMED Actual EBITDA CAGR:1Y: 44.16%2Y: 48.55%5Y: 28.73%10Y: 20.08%

Ratios, Profit Margins & Return on Capital:

GMED - Net Profit Margin
GMED Net Profit Margin CAGR:1Y: -29.46%2Y: 95.18%5Y: 3.02%10Y: 0.23%
GMED - Gross Profit Margin
GMED Gross Profit Margin CAGR:1Y: 4.20%2Y: 8.75%5Y: -1.42%10Y: -0.93%
GMED - Price to Earnings
GMED Price to Earnings CAGR:1Y: 79.29%2Y: -50.60%5Y: -17.75%10Y: -2.22%
GMED - Price To Sales Ratio
GMED Price To Sales Ratio CAGR:1Y: 26.51%2Y: -3.62%5Y: -15.28%10Y: -1.99%
GMED - Return on Capital Employed
GMED Return on Capital Employed CAGR:1Y: 117.09%2Y: 75.57%5Y: 6.18%10Y: -2.61%
GMED - Return on Invested Capital
GMED Return on Invested Capital CAGR:1Y: 73.35%2Y: 101.58%5Y: 4.83%10Y: -0.96%

Compare stocks side-by-side

Projected Future Returns & Dividends for GMED

Based on past 10-year performance, here are GMED growth metrics:

Share price CAGR of +13.04%
Dividend CAGR of +0%

Using GMED CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

GMED (DRIP)GMED - No DRIP
Current Price$78.68$78.68
Start Shares127.10127.10
Start Value$10,000$10,000
  
After 10 years:
Final Share Count127.10127.10
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$78.68$78.68
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - GMED

NOTE: Above numbers are our estimate based on GMED's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
Combined 55% Lifetime Discount

Company Info

Globus Medical, Inc. (GMED) had its IPO on 2012-08-03, and is traded on NYSE stock exchange.

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

GMED website: https://www.globusmedical.com


Get Full Access to All Reports with DRIPCalc PRO

Get 3 Months Free with Annual Plan
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
Combined 55% Lifetime Discount
Loading signals…

DCF Model — GMED

Value from:
Pay up to today
—
vs current price $78.68
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →